Message-ID: <E41334E9-F755-4EBA-98FC-472DEE4D8D76@gmail.com>
Date: 2019-03-14T10:37:14Z
From: Peter Dalgaard
Subject: Rank ANCOVA
In-Reply-To: <VI1PR04MB5488035B17D6AB450F6349B9B34A0@VI1PR04MB5488.eurprd04.prod.outlook.com>
1. This is the R-help mailing list, not "Frank and Dennis"
2. You seem to be referring to two posts from July 2010 by Frank Harrell and Dennis Fisher.
-pd
> On 13 Mar 2019, at 12:06 , Jackson, Daniel <daniel.jackson1 at astrazeneca.com> wrote:
>
> Hi Frank and Dennis
>
> I am in a similar situation but I would prefer to use a proportional odds model. 2 questions.
>
>
> 1. Has rank ancova been implemented in R now, despite its short comings?
> 2. Where has it been shown to yield unreliable analyses? I would like this evidence (which I believe but I would like to convince others!).
>
> Thanks, Dan
> ________________________________
>
> AstraZeneca UK Limited is a company incorporated in =\...{{dropped:26}}